First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug ...
Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...
Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.
Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...
Elasmogen Ltd. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer, autoimmune and ...
Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...
To determine who could benefit from targeted cancer treatments, a researcher at the University of Missouri has put tumors under a spotlight.
In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal ...
Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...
Backers claim the tests can predict a child’s risk of autism using a strand of hair or a mother’s blood, but critics say they are not ready for the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback